Loading quotes...

Forecast

The analysts' average price target is €105.35 (-40.18%). The median is €114.41 (-35.04%).

Buy	8
Hold	15
Sell	6

News Go to news feed

Moderna shares fall after analyst downgrade and cautious data on Intismeran

Moderna shares drop about eight percent, extending a correction after preliminary Intismeran data leaked. William Blair removed its buy rating and downgraded to "Market Perform", saying the success of the personalized melanoma vaccine still needs to be demonstrated in other tumor types. Analysts see potential for a new treatment standard but warn of substantial clinical and biological risks in expanding to kidney, bladder and lung cancer. » More on deraktionaer.de
Moderna defends cancer vaccine intismeran after share-price slide

Despite positive Phase‑3 data for intismeran and a combination therapy with Keytruda that reduced the risk of relapse or death in high‑risk melanoma patients by 42%, Moderna shares fell after a data leak and profit‑taking. CEO Stéphane Bancel urged investors to focus on the data and compared intismeran’s long‑term potential with Merck’s Keytruda, but stressed that further study results will be decisive. If efficacy is confirmed in other cancers, Moderna could become a major competitor in the mRNA cancer market and increase pressure on BioNTech. » More on finanzen.net
Moderna stock falls after disappointing details from Phase 3 trial for skin cancer vaccine

Details of the Phase 3 trial by Moderna and Merck leaked ahead of the ESMO presentation and do not fully meet the high expectations. The stock falls about eight percent as investors take profits. CEO Stéphane Bancel stresses the real clinical benefit but warns that the personalized vaccine approach will not work everywhere. » More on deraktionaer.de

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Moderna Inc. has already paid €0.17 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Moderna Inc. had revenue of €127.05M and net profit of -€685.2M

(EUR)	June 2026	YoY
Revenue	127.05M	5.46%
Gross profit	45.56M	133.49%
Net profit	-685.2M	2.11%
EBITDA	-616.85M	4.33%

Fundamentals

Metric	Value
Market capitalization	€71.69B
Number of shares	399.24M
52-week high/low	€228.35 - €19.99
Dividends	No
Beta	0.90
P/E ratio	-25.08
PEG ratio	2.97
P/B ratio	11.72
P/S ratio	35.86

Company profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Name	Moderna Inc.
CEO	Stéphane Bancel
Headquarters	Cambridge, ma USA
Website	investors.modernatx.com/overview/default.aspx
Sector	Health Care
Industry	Biotechnology
IPO	12/07/2018
Employees	4,700